API

Polidocanol (30mg)

Drug classification

Vascular sclerosing agent; non-ionic detergent sclerosant.

Dosage form

Sterile solution for injection, intended for intravenous or intravariceal use.

API strength per dosage

Dose

Asklerol 3% Injection (Polidocanol 30 mg/mL) is typically used for sclerotherapy of varicose veins. Dosage depends on vein size and clinical judgment; do not exceed recommended total volume per session. Safety and efficacy in children are not established. Use caution in patients with severe hepatic or renal impairment; consult product information for details.

Mechanism of action

Polidocanol acts as a non-ionic surfactant that disrupts the lipid molecules in the cell membranes of vascular endothelium. This endothelial damage induces localized thrombosis and subsequent fibrosis, leading to vessel sclerosis and closure. Its primary target is the vascular endothelial cell membrane.

Indications

Varicose veins

Side effects

Injection site pain Pain in extremities Thrombophlebitis

Pregnancy category

Polidocanol safety in pregnancy is not established; use only if clearly needed and potential benefits outweigh risks. Animal data are limited; human data lacking.

Precautions

Hypersensitivity reactions, tissue necrosis risk if extravasation occurs, avoid intra-arterial injection, monitor for thromboembolic events, use caution in patients with severe arterial disease, monitor for allergic reactions, avoid use in bedridden patients, observe for local pain or inflammation, monitor injection site, resuscitation equipment available.

Contraindications

Known allergy to polidocanol, acute thromboembolic diseases, severe arterial disease, infection at injection site, bedridden patients, severe systemic infections, uncontrolled diabetes, pregnancy, lactation, severe asthma, acute superficial thrombophlebitis.